{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-019087","form_type":"8-K","ticker":"DARE","cik":"0001401914","company_name":"Dare Bioscience, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.254957+00:00","generated_at":"2026-06-02T00:35:55.182947+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Daré Bioscience Q1 cash $3.6M, secures $22M royalty financing; Ovaprene Phase 3 ongoing","bullets":["Cash & equivalents $3.6M at March 31, 2024; subsequent $22M non-dilutive royalty financing from XOMA and $1M grant installment.","R&D expenses $3.3M in Q1 2024, down 34% YoY from $5.0M; G&A $2.7M vs $3.3M.","Ovaprene Phase 3 contraceptive study recruiting at 18 US sites; central ad campaign launched March 2024.","Sildenafil Cream end-of-Phase 2 meeting with FDA completed; additional feedback expected 2Q2024 for Phase 3 design.","XACIATO commercialized by Organon since Q4 2023; first FDA-approved product from Daré portfolio."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-019087","json":"https://secwatch.observer/filing/0001493152-24-019087.json","markdown":"https://secwatch.observer/filing/0001493152-24-019087.md","text":"https://secwatch.observer/filing/0001493152-24-019087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401914/000149315224019087/0001493152-24-019087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401914/000149315224019087/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:35:55.182947+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ad248e04c1cf17fb9ab3ce76a23601bc1bfbeaad","claim":"Dare Bioscience, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"Daré Bioscience, Inc. (the “Company”), issued a press release announcing its financial results for the quarter ended March 31, 2024, a copy of which is furnished as Exhibit 99.1 to this report.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401914/000149315224019087/0001493152-24-019087-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}